GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tryptamine Therapeutics Ltd (ASX:TYP) » Definitions » Shareholder Yield %

Tryptamine Therapeutics (ASX:TYP) Shareholder Yield % : -5.72% (As of Dec. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Tryptamine Therapeutics Shareholder Yield %?

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return. As of today, Tryptamine Therapeutics's Shareholder Yield % was -5.72%.


Tryptamine Therapeutics Shareholder Yield % Historical Data

The historical data trend for Tryptamine Therapeutics's Shareholder Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tryptamine Therapeutics Shareholder Yield % Chart

Tryptamine Therapeutics Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Shareholder Yield %
Get a 7-Day Free Trial - -21.69 -24.72 -7.37 -16.40

Tryptamine Therapeutics Semi-Annual Data
Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Dec24
Shareholder Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.37 -13.81 -16.40 23.45 -5.26

Competitive Comparison of Tryptamine Therapeutics's Shareholder Yield %

For the Biotechnology subindustry, Tryptamine Therapeutics's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tryptamine Therapeutics's Shareholder Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tryptamine Therapeutics's Shareholder Yield % distribution charts can be found below:

* The bar in red indicates where Tryptamine Therapeutics's Shareholder Yield % falls into.


;
;

Tryptamine Therapeutics Shareholder Yield % Calculation

Tryptamine Therapeutics's Shareholder Yield % for the quarter that ended in Dec. 2024 is calculated as:

Shareholder Yield %=Dividend Yield %+Buyback Yield %+Net Debt Paydown Yield %
=0.00 %+-5.26 %+0 %
=-5.26 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.


Tryptamine Therapeutics  (ASX:TYP) Shareholder Yield % Explanation

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."

Shareholder Yield % is calculated by three components: Dividend Yield %, Buyback Yield %, and Net Debt Paydown Yield %.

Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.

Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.

Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.


Tryptamine Therapeutics Shareholder Yield % Related Terms

Thank you for viewing the detailed overview of Tryptamine Therapeutics's Shareholder Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Tryptamine Therapeutics Business Description

Traded in Other Exchanges
Address
C/o Bio101 Financial Advisory Pty Ltd, 697 Burke Road, Suite 201, Camberwell, Melbourne, VIC, AUS, 3124
Tryptamine Therapeutics Ltd is a clinical-stage biotechnology company focused on bringing transformative medicine with known safety profiles to diseases with no effective first-line treatments. The programs are designed to address neuropsychiatric disorders through the therapeutic dosing of synthetic psilocybin and IV infused psilocin in conjunction with psychotherapy. Its product pipeline includes TRP-8803 (IV-infused psilocin) and TRP-8802 (oral psilocybin).

Tryptamine Therapeutics Headlines

No Headlines